Understanding Gene ENvironment Interaction in ALcohol-related hepatocellular carcinomacore
GENIAL · Horizon Europe grant · 2023-01-01–2027-12-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-MISS-2021-CANCER-02 · scheme HORIZON-RIA · topic HORIZON-MISS-2021-CANCER-02-03. CORDIS record →
Objective
Alcohol-related hepatocellular carcinoma (ALD-HCC) is, in Europe, the leading cause of liver cancer (2nd most common cause of cancer-related death worldwide, affecting both men and women). ALD-HCC has a median 5-year survival rate of 15%. Yet, the prognosis is driven by the tumour stage, with curative options providing a 5-year survival exceeding 70% for early-stage HCC (<20% of cases). Therefore, interventions aiming to improve prevention and early detection are key. ALD-HCC results from the interplay between environmental determinants and genetic variations. A comprehensive characterisation of environmental factors (e.g. diet, lifestyle) linked to ALD-HCC is still lacking. We recently performed the 1st genome-wide association study of ALD-HCC and identified predisposing genetic variations. However, their role on alcohol-related liver carcinogenesis needs clarification and the genetic architecture of ALD-HCC remains mostly unknown. GENIAL brings together partners with unique expertise in clinical hepatology, single-cell and spatial multi-omics, artificial intelligence (AI) and communication and dissemination capacities. Our aim is to 1) portray genetic and environmental determinants promoting ALD-HCC; 2) evaluate how they interact at cellular level in human samples and preclinical models to get novel insights into liver carcinogenesis, and identify chemopreventive targets; and 3) assess how these determinants modulate the ALD-HCC risk in prospective cohorts of patients included in HCC surveillance programs. Environmental factors will be comprehensively characterised in an ongoing clinical trial designed to evaluate alternative methods for early-stage HCC detection. Finally, AI models, reaching the minimal viable product stage by the end of GENIAL, will be used to integrate genetic and non-genetic information (including digital imaging) to develop novel cost-effective strategies towards prevention and early-stage detection of ALD-HCC in at-risk individuals.This action is part of the Cancer Mission cluster of projects on ‘‘Understanding’.
Beneficiaries (14)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| UNIVERSITE LIBRE DE BRUXELLES | BE | coordinator | €1,306,338 | |
| INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | FR | participant | €2,613,758 | |
| ASSISTANCE PUBLIQUE HOPITAUX DE PARIS | FR | participant | €1,769,425 | |
| TECHNISCHE UNIVERSITAET DRESDEN | DE | participant | €1,534,875 | |
| FUNDACAO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD | PT | participant | €1,500,938 | |
| StratiPath AB | SE | participant | €667,975 | Yes |
| UNIVERSITE PARIS CITE | FR | participant | €605,000 | |
| UNIVERSITA DEGLI STUDI DI MILANO | IT | participant | €494,094 | |
| VIB VZW | BE | participant | €417,219 | |
| EPSA INNOVATION FRANCE | FR | participant | €414,375 | |
| UNIVERSITE PARIS 13 | FR | participant | €393,845 | |
| EUROPEAN LIVER PATIENTS ASSOCIATION | BE | participant | €83,375 | |
| FONDAZIONE IRCCS CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO | IT | thirdParty | €0 | |
| EUROPEAN ASSOCIATION FOR THE STUDYOF THE LIVER | CH | associatedPartner | — |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.